Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in
adults with major depressive disorder (MDD) and borderline personality disorder (BPD).